


Tailoring treatment for your patients with mRCC: the experts answer your questions



Invitation

17:00–19:00, Friday 26 September 2014

North Centre, Bilbao Auditorium, IFEMA

Dear Colleague

I am very pleased to invite you to the Pfizer Oncology satellite symposium 'Tailoring treatment for your patients with mRCC: the experts answer your questions'.

Navigating the current treatment paradigm in metastatic renal cell carcinoma (mRCC) is a complex issue.

In this symposium, we will seek to address some of the complexities associated with the management of patients with mRCC by providing our experience-based recommendations and by answering your questions. We will explore evidence-based recommendations for treatment-naïve patients and options for patients after progression on first-line treatment, including choice of second-line therapy, dosing and treatment duration decisions, and management of adverse events. Finally, we will consider the future of mRCC treatment, examining preliminary evidence for new targets/mechanisms of action or new strategies, such as immunotherapies and vaccines.

During this meeting, you have the opportunity to interact with us. What questions around the selected themes have you always wanted answering? Vote for your hot topics, and submit your questions during the live session!

We look forward to a highly interactive and informative event.

Manuela Schmidinger (Chair)
Medical University of Vienna, Vienna, Austria

Programme

- 17:00–17:10 Welcome and introduction
Manuela Schmidinger (Austria)
- 17:10–17:35 Exploring the options for treatment-naïve patients with mRCC
Manuela Schmidinger (Austria)
- 17:35–18:00 Exploring the options for pre-treated patients with mRCC
Lisa Pickering (UK)
- 18:00–18:25 Optimising therapy management
Eduard Vrdoljak (Croatia)
- 18:25–18:50 New approaches to mRCC treatment
Joaquim Bellmunt (Spain)
- 18:50–19:00 Summary and close
Manuela Schmidinger (Austria)